Home/Gilgamesh Pharmaceuticals/Andrew Kruegel, PhD

AK

Andrew Kruegel, PhD

Co-Founder, CSO

Gilgamesh Pharmaceuticals

Therapeutic Areas

Major Depressive Disorder Anxiety Disorders Opioid Use Disorder Psychiatric Diseases

Gilgamesh Pharmaceuticals Pipeline

Drug	Indication	Phase
NMDAR Antagonist (GM-2505/Bretisilocin)	Major Depressive Disorder	Phase 2
Neuroplastogen (GM-1020)	Major Depressive Disorder	Phase 2a
Safer Ibogaine Analogs	Opioid Use Disorder	Pre-clinical/Research

Leadership Team at Gilgamesh Pharmaceuticals

Jonathan Sporn, MD

Jorge Quiroz, MD MBA

Chief Development & Strategy Officer (CDSO)

Gerard Marek, MD PhD

Chief Medical Officer (CMO)

Laszlo Kiss, PhD

Chief Business Officer & Head of Research

View full Gilgamesh Pharmaceuticals profile